Early intestinal barrier changes in A53T transgenic Parkinson’s disease mice
Cell and Tissue Research · 2026-04 · 404 (1)
DOI: 10.1007/s00441-026-04062-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell and Tissue Research, online erschienen am 24.03.2026. Verfasst von Myat Noe Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gut Barrier and Disease Laboratory, Department of Anatomy and Physiology, University of Melbourne, Parkville, VIC, 3010, Australia. Hauptthemen laut MEDLINE: Parkinson Disease, alpha-Synuclein, Intestinal Mucosa. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, University of Melbourne, Jack Brockhoff Foundation.
Abstract (Originalsprache)
Gut dysfunction commonly precedes motor symptoms in Parkinson’s disease (PD), but the mechanistic sequence of gut versus brain pathology remains unclear. This work aimed to define the timing of intestinal barrier dysfunction relative to central nervous system (CNS) changes in the A53T α-synuclein transgenic mouse model of PD. Functional and molecular assessments of the gastrointestinal tract (ileum and colon) were conducted at 12 and 36 weeks. We measured in vivo and ex vivo intestinal permeability, nutrient absorption, histomorphology, goblet cell density, and expression of MUC2 and Claudin-1. Inflammatory markers (CRP, TNF-α, CD45) were quantified in plasma and gut tissues. A53T mice exhibited increased intestinal permeability at 12 and 36 weeks, with transiently elevated ex vivo transepithelial electrical resistance (TER) at 12 weeks. Nutrient absorption remained intact. Morphological changes included widened villi and crypts, altered mucin expression, and early reductions in Claudin-1 in the ileum and the colon while inflammatory markers remained largely unchanged. These findings suggest that gut dysfunction precedes known central pathology in A53T mice, supporting further investigation into the gut as an early site of pathology and a potential therapeutic target in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gut Barrier and Disease Laboratory, Department of Anatomy and Physiology, University of Melbourne, Parkville, VIC, 3010, Australia.
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, 3010, Australia.
- Department of Optometry and Vision Sciences, University of Melbourne, Parkville, VIC, 3010, Australia.
- Gut Barrier and Disease Laboratory, Department of Anatomy and Physiology, University of Melbourne, Parkville, VIC, 3010, Australia. rachel.mcquade@unimelb.edu.au.
Förderung
- National Health and Medical Research Council
- University of Melbourne
- Jack Brockhoff Foundation
Zitieren
APA
Han, M. N., Artaiz, O., Rowe, M. C., Finkelstein, D. I., Diwakarla, S., & McQuade, R. M. (2026). Early intestinal barrier changes in A53T transgenic Parkinson’s disease mice. Cell and Tissue Research, 404(1). https://doi.org/10.1007/s00441-026-04062-9
Vancouver
Han MN, Artaiz O, Rowe MC, Finkelstein DI, Diwakarla S, McQuade RM. Early intestinal barrier changes in A53T transgenic Parkinson’s disease mice. Cell and Tissue Research. 2026;404(1). doi:10.1007/s00441-026-04062-9
BibTeX
@article{Han2026,
author = {Han, Myat Noe and Artaiz, Olivia and Rowe, Matthew C and Finkelstein, David I and Diwakarla, Shanti and McQuade, Rachel M},
title = {Early intestinal barrier changes in A53T transgenic Parkinson’s disease mice},
journal = {Cell and Tissue Research},
year = {2026},
volume = {404},
number = {1},
doi = {10.1007/s00441-026-04062-9}
}
EUVIMED